Myocardial Infarction
Conditions
Keywords
Glucagon-like peptide-1, Non-ST-segment elevation myocardial infarction, Left ventricular ejection fraction
Brief summary
The investigators planned to evaluate the effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction (NSTEMI).
Detailed description
Patients with non-ST-segment elevation myocardial infarction (NSTEMI) are a heterogeneous group with respect to the risk of having a major adverse cardiac event (MACE). Elevation of blood glucose is a common metabolic disorder among patients with acute myocardial infarction (AMI) and is associated with adverse prognosis. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose. GLP-1 analogues have significant cardiovascular protective effects in patients with AMI. GLP-1 may have antioxidant and anti-inflammatory properties, and protect endothelial function. Studies in conscious, chronically instrumented dogs demonstrated that GLP-1 infusion increases insulin sensitivity and myocardial glucose uptake in postischemic contractile dysfunction and dilated cardiomyopathy. Liraglutide, a GLP-1 analogue, was reported to reduce cardiac rupture and infarct size and improve cardiac output in normal and diabetic mice. Continuous infusion of GLP-1 (1.5 pmol/kg/min) has been shown to improve functional recovery in patients with AMI complicated by decreased left ventricular function GLP-1 could protect against ischemia-reperfusion injury and improve cardiac function in patients with acute ST-segment elevation myocardial infarction. However, the effects of GLP-1 on NSTEMI patients remain unclear. The aim of this study was to evaluate the effects of liraglutide on left ventricular function in patients with NSTEMI.
Interventions
DRUGGLP-1
GLP-1 were taken daily for 7 days
DRUGPlacebo
Placebo were taken daily for 7 days
Sponsors
Chinese PLA General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
non-ST-segment elevation myocardial infarction (NSTEMI )
Exclusion criteria
1. unconscious at presentation 2. had ST-segment elevation acute myocardial infarction 3. NSTEMI requiring emergency percutaneous coronary angiography 4. valvular heart disease 5. cardiogenic shock 6. hypoglycaemia 7. diabetic ketoacidosis 8. had a history of myocardial infarction 9. stent implantation 10. renal insufficiency 11. had previously undergone coronary artery bypass surgery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| left ventricular ejection fractions | at 3 months | The primary efficacy endpoint was the effect of liraglutide on left ventricular ejection fractions (LVEF) measured by transthoracic echocardiography at 3 months . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 6-minute walk distance | at 3 months | The change in6-minute walk distance at 3 months after treatment. |
| treatment-emergent adverse events | at 3 months | Treatment-emergent adverse events (TEAEs): hypoglycaemia, pancreatitis, thyroid cancer |
Countries
China
Contacts
Primary ContactWei Ren Chen, M.D.
Outcome results
None listed